Biotech Expands to Boston
Biotech Firm Chosa Oncology Opens Boston Office to Advance US Market Entry
Chosa Oncology AB has set up its first US office in Boston, Massachusetts, marking a key step toward launching Platin-DRP in the American market. MarketScreener reports the move as a direct signal that the company is shifting from research to commercial operations. CEO Peter Buhl Jensen called Boston "not just a location" but "an ecosystem that understands the value of precision medicine."
Platin-DRP is a gene expression-based biomarker tool. In plain terms, it uses a 200-gene test to predict which cancer patients will actually respond to platinum-based chemotherapy — drugs like cisplatin. The company is now preparing a step-by-step US market entry, MarketScreener confirmed.
A Precision Medicine Bet on Metastatic Breast Cancer
Chemotherapy has long been a "one-size-fits-all" treatment. Chosa's DRP platform challenges that model. It analyzes mRNA signals from 200 genes to score how likely a patient is to respond to a drug before they take it. In Phase 2 trials, DRP-selected patients reached a median progression-free survival of 7.5 months — significantly higher than unselected groups.
The target patient group is large. Roughly 150,000 women in the US are living with metastatic breast cancer. For many, Platin-DRP could offer a targeted option at a late stage of treatment. The FDA has increasingly supported this kind of "biomarker-first" approach under its Precision Medicine initiative, which aligns with the 21st Century Cures Act.
Why Boston — and Why Now
Chosa chose Boston because of its dense biotech ecosystem. The city's Kendall Square and Seaport district house hundreds of life sciences firms and top research hospitals, including Dana-Farber Cancer Institute. The Massachusetts Life Sciences Center helped facilitate the move with logistical support and tax incentives. The office is expected to create 40 to 60 high-paying jobs within 18 months.
The timing is strategic. Chosa is listed on Nasdaq First North Growth Market in Sweden — a smaller exchange. Analysts at BioWorld and Endpoints News suggest the Boston move is a precursor to a potential NASDAQ dual listing or IPO. US-listed biotech firms historically trade at a 2.5 times valuation premium over their Nordic counterparts, according to financial data from Dagens Industri.
Phase 3 Trial and a $25–$30 Million Fundraising Target
The Boston office will serve as the nerve center for Chosa's upcoming Phase 3 registrational trial. That trial — the final stage required for FDA approval — is estimated to cost $25 to $30 million. The company plans to raise most of that capital from US-based venture investors. Pre-IND meetings with the FDA were conducted in late 2024 and early 2025 to align on the trial design.
MarketScreener confirmed the company is preparing for a "stepwise" US market entry — meaning it will build its presence in stages rather than launching all at once. Jensen has framed the move as proof that Platin-DRP is "no longer a research project, but a commercial-ready asset."
Big Pharma M&A Eyes and a European Brain Drain Debate
Chosa's biomarker-first strategy has drawn attention from bigger players. Industry analysts say the company could become an M&A target for large pharmaceutical firms like Pfizer or Merck, both of which are actively building out their late-stage oncology pipelines. A proven companion diagnostic — one that tells doctors exactly who will respond — is a rare and valuable asset in drug development.
Not everyone celebrates the move. Some European policy analysts view it as "capital flight" — a sign that promising science born in Scandinavia must relocate to the US to survive. Skeptical investors also warn that clinical trial costs in Boston are far higher than in Eastern Europe or Asia, which could drain the company's cash faster than projected. The stakes, on both sides, are high.
Sentiment
NeutralPublishers
3
Articles
4
Reach
5
